Covid | 'Oxford vaccine's late stage trials to start in a week in India': ICMR
At present country has three Indian COVID-19 vaccines which are in different phases of clinical testing, said Indian Council of Medical Research (ICMR) Director General Dr Balram Bhargava on Tuesday.
Addressing a press conference in the national capital, he said, "At the present moment, we have three Indian vaccines which are in different phases of clinical testing.
The 2 vaccines- Bharat Biotech vaccine and DNA vaccine of Zydus Cadila have completed phase 1 and will begin phase 2 while third is Oxford vaccine." "Oxford vaccine, being manufactured by Serum Institute of India (SII) got approval for phase 2 and 3 clinical trials, which are starting within a week at 17 sites," he added.
Dr Bhargava, however, said that social distancing and proper hygiene are the best "vaccine" available now and even after.
"Physical Distancing, wearing a mask, proper hand hygiene are the best vaccine available at the moment and even after.
We will have to continue with these measures," he said.
India has so far recorded over 18 lakh cases and more than 38,900 deaths.
Director General of the Indian Council of Medical Research (ICMR), Dr Balram Bhargava said three vaccine candidates are at different clinical trial stages in India. Covid-19 vaccine candidates being manufactured by Cadila Healthcare and Bharat Biotech have completed the first phase of the trial while the Serum Institute of India (SII) will begin with Phase 3 trial after getting the nod, Balram Bhargava, ICMR’s director general, said during the health ministry’s briefing.The Pune-based Serum Institute will conduct the Phase 3 trial on 1,500 volunteers across 14 locations, Bhargava added.
Credit: HT Digital Content Duration: 01:19Published
Director General of Indian Council of Medical Research, Balram Bhargava on September 15 informed about the COVID-19 vaccines trial stage in India. He said, Cadila and Bharat Biotech have completed phase-I trials and Serum Institute has completed phase II-B3 trials, and will start phase-III trials after clearance. He said, "3 vaccines are at clinical trial stage in India. Cadila and Bharat Biotech have completed phase-I trials. Serum Institute has completed phase II-B3 trials, and will start phase-III trial (with 1500 patients at 14 locations) after clearances."
Indian Council of Medical Research, Director General Dr. Balram Bhargava during Health Ministry's briefing on COVID-19 situation in India informed about the sero survey publication. Bhargava said, "ICMR sero survey is publication in-progress. It should appear by this week in the Indian Journal of Medical Research. It has been peer reviewed. The second national sero-survey should be completed in the first week September". On situation of COVID-19 vaccines in India, Balram Bhargava said, "Three COVID-19 vaccines are ahead in the race in India. Serum Institute's vaccine is in phase 2(B) and phase 3 trials and Bharat Biotech and Zydus Cadila's vaccines have completed phase 1 trial."
Indian Council of Medical Research, Director General Balram Bhargava when asked on who is diving the pandemic, said, "Irresponsible, less cautious people who are not wearing masks are driving the pandemic in India." He further reacted on re-infection of one case in Hong Kong. He said, "We have read report on re-infection of one case in Hong Kong. It can depend on several factors. It could be related to the patient's immune status, whether the virus has mutated. We need to closely follow it up, but at the same time we don't need to be alarmed".
India's COVID-19 tally crossed 56-lakh mark on September 23 with a spike of 83,347 new infections. Total COVID-19 cases in the country stand at 56,46,011. Currently, there are 9,68,377 active cases. With 1,085 deaths in last 24 hours, the death toll rises to 90,020. Indian Council of Medical Research reported that 6,62,79,462 samples were tested up to September 22. Further, the Health Ministry informed that India's COVID-19 testing capacity surges to over 12 lakh daily tests.
India's COVID tally crossed 55-lakh mark on September 22 after the country reported a spike of 75,083 new COVID-19 cases. Total COVID case tally stands at 55, 62,664, including 9,75,861 active cases, 44,97,868 discharged. With 1,053 deaths in the last 24 hours, death toll due to COVID reached 88,935. Indian Council of Medical Research reported that 6,53,25,779 samples were tested up to September 21 for the virus. Of these, 9,33,185 samples were tested on September 21.
In the last 24 hours, 12 lakh COVID tests were conducted across the country which is an all-time record high. India's total number of coronavirus tests is more than 6.37 crore so far. Meanwhile, India's COVID-19 case tally crossed 54-lakh mark with a spike of 92,605 new cases and 1,133 deaths in last 24 hours. According to Ministry of Health and Family Welfare, the total case tally stands at 54,00,620 including 10,10,824 active cases, 43,03,044 cured/discharged/migrated and 86,752 deaths. As per Indian Council of Medical Research (ICMR), 6,36,61,060 samples were tested up to 19th Sep, of these, 12,06,806 samples were tested yesterday.
Health Minister of Delhi, Satyendar Jain on September 19 briefed media over the current situation of COVID-19 in national capital. He said, "When people in such large numbers are getting infected in Delhi and other parts of the country, it should've been admitted that there is community spread... but only ICMR or Central govt can comment on this."
From the CEO of the world's largest vaccine manufacturer commenting on the possible timeline of the final vaccine reaching every person on the planet, to the World Health Organisation warning that the months of October and November 2020 could be 'tougher' - here are the top news updates on the Covid-19 pandemic. Adar Poonawalla, chief executive of Serum Institute of India reportedly said that it might take 4-5 years for the vaccine to reach everyone. He estimated that around 1,500 crore vaccine doses would be required to inoculate everyone if the final vaccine is a 2-dose drug. Meanwhile, the Government of India banned the export of onions after a 30% jump in export of the kitchen staple in the April-July 2020 period. Over a dozen Members of Parliament were found to be Covid positive on the day the central legislative body convened for its monsoon session. In Delhi, the deputy Chief Minister, Manish Sisodia, tested positive on the day that the Chief Minister of neighbouring Haryana, Manohar Lal Khattar, finally recovered from the disease. Watch the full video for the other top updates on the spread of the Sars-CoV-2 coronavirus.
Credit: HT Digital Content Duration: 02:18Published
The Phase II human clinical trial of the Oxford COVID-19 vaccine candidate, being manufactured by the city-based Serum Institute of India (SII), began at a medical college and hospital here on Wednesday. SII, with ICMR guidelines, chose five volunteers who were given the first dose of vaccine. The volunteers were given the vaccine at Pune's Bharti Hospital. The volunteers will be monitored by SII, Bharti hospital, and ICMR.
Credit: HT Digital Content Duration: 02:01Published
From another minister in the Narendra Modi cabinet testing positive for infection, to the progress report of India's indigenously-developed vaccine candidates - here are the top news updates on the Covid-19 pandemic. Union minister of petroleum and natural gas, and steel, Dharmendra Pradhan, tested positive days after Union Home minister Amit Shah confirmed his positive diagnosis. Meanwhile, other members of the Union cabinet, like Ravi Shankar Prasad and Babul Supriyo, are quarantining themselves as a precaution. On the medical front, India's two vaccine candidates have completed phase 1 of human clinical trials. The vaccines have been developed by Bharat Biotech, ICMR and Zydus Cadila. The Jammu and Kashmir administration has decided to allow all places of worship to reopen from August 16. Earlier, the authorities had decided to cancel the annual Amarnath Yatra due to the Covid pandemic. In economic news, the International Monetary Fund has said that Covid might exacerbate the narrowing of global current account imbalances which was happening due to trade slowdown in 2019. Watch the full video for the other updates on the spread of the Sars-CoV-2 coronavirus.
Credit: HT Digital Content Duration: 02:41Published
Post Graduate Institute (PGI) Rohtak will start the phase-2 human clinical trial of Bharat Biotech's COVID-19 vaccine. “We got permission from Bharat Biotech to start a phase-2 human clinical trial of their vaccine. We've 300 volunteers, aged between 12 years and 65- years, out of which screening of 15 has been completed,” said Dr OP Kalra, vice-chancellor, PGI Rohtak. Kalra also informed that in the phase-2 trail, they have recruited volunteers who have controlled diabetes and high blood pressure. Watch the full video for more details.
Credit: HT Digital Content Duration: 01:48Published
Post Graduate Institute (PGI) Rohtak will start the phase-2 human clinical trial of Bharat Biotech's COVID-19 vaccine. Speaking to ANI, Dr OP Kalra, vice-chancellor, PGI Rohtak said, "We got permission from Bharat Biotech to start a phase-2 human clinical trial of their vaccine. We've 300 volunteers, aged between 12 years and 65- years, out of which screening of 15 has been completed."
Credit: ANI Duration: 01:32Published
Tweets about this
बसन्त _जी:(_0001 RT @CNNnews18: The late-stage trials of the experimental vaccine, developed with researchers from the University of Oxford, were suspended… 2 hours ago
CNNNews18 The late-stage trials of the experimental vaccine, developed with researchers from the University of Oxford, were s… https://t.co/crGV1UCuVV 2 hours ago
@Back2thebedroom RT @DrGurdeepParhar: Late-stage COVID-19 vaccine trial on pause due to possible serious side effect. Here's what that means https://t.co/V… 9 hours ago
Gurdeep Parhar Late-stage COVID-19 vaccine trial on pause due to possible serious side effect. Here's what that means https://t.co/VPDAidG1lS 9 hours ago
Andrea Doyle RT @CBCAlerts: AstraZeneca says UK clinical trials resuming for its experimental coronavirus vaccine after late-stage trials had been suspe… 11 hours ago